OBJECTIVES: We have recently shown that ghrelin, a novel orexigenic hormone, is reduced in sepsis. Ghrelin treatment, mediated through ghrelin receptors in the brain, attenuates sepsis-induced inflammation and mortality. Gut barrier dysfunction is common in sepsis. High-mobility group B1 (HMGB1) increases gut permeability both in vitro and in vivo. However, it remains unknown whether ghrelin has any effects on HMGB1 and gut barrier function in sepsis. We hypothesized that ghrelin decreases HMGB1 release and attenuates sepsis-induced gut barrier dysfunction through central ghrelin receptors. DESIGN: Prospective, controlled, and randomized animal study. SETTING: A research institute laboratory. SUBJECTS: Male adult Sprague-Dawley rats (275-325 g). INTERVENTIONS: Cecal ligation and puncture (CLP) followed by injection/infusion of ghrelin. MEASUREMENTS AND MAIN RESULTS: Five hours after CLP, a bolus intravenous injection of 2 nmol of ghrelin was followed by a continuous infusion of 12 nmol of ghrelin via an osmotic mini-pump for 15 hrs. Twenty hours after CLP, brain ghrelin levels, serum HMGB1 levels, ileal mucosal permeability to fluorescein isothiocyanate dextran, bacterial counts in the mesenteric lymph nodes complex, and gut water content were determined. In additional groups of animals, bilateral trunk vagotomy was performed at 5 hrs after CLP before ghrelin injection. Furthermore, to confirm the role of central ghrelin receptors in ghrelin's effect, ghrelin (1 nmol) was administered through intracerebroventricular injection at 5 hrs after CLP. Our results showed that brain levels of ghrelin decreased by 34% at 20 hrs after CLP. Intravenous administration of ghrelin completely restored brain levels of ghrelin, significantly reduced the elevated HMGB1 levels, and attenuated gut barrier dysfunction. Vagotomy eliminated ghrelin's inhibition of HMGB1 and attenuation of gut barrier dysfunction. Intracerebroventricular injection of ghrelin decreased serum HMGB1 levels and ameliorated gut barrier dysfunction. CONCLUSIONS: Ghrelin reduces serum HMGB1 levels and ameliorates gut barrier dysfunction in sepsis by vagus nerve activation via central ghrelin receptors. Ghrelin can be further developed as a novel agent to protect gut barrier function in sepsis.
OBJECTIVES: We have recently shown that ghrelin, a novel orexigenic hormone, is reduced in sepsis. Ghrelin treatment, mediated through ghrelin receptors in the brain, attenuates sepsis-induced inflammation and mortality. Gut barrier dysfunction is common in sepsis. High-mobility group B1 (HMGB1) increases gut permeability both in vitro and in vivo. However, it remains unknown whether ghrelin has any effects on HMGB1 and gut barrier function in sepsis. We hypothesized that ghrelin decreases HMGB1 release and attenuates sepsis-induced gut barrier dysfunction through central ghrelin receptors. DESIGN: Prospective, controlled, and randomized animal study. SETTING: A research institute laboratory. SUBJECTS: Male adult Sprague-Dawley rats (275-325 g). INTERVENTIONS: Cecal ligation and puncture (CLP) followed by injection/infusion of ghrelin. MEASUREMENTS AND MAIN RESULTS: Five hours after CLP, a bolus intravenous injection of 2 nmol of ghrelin was followed by a continuous infusion of 12 nmol of ghrelin via an osmotic mini-pump for 15 hrs. Twenty hours after CLP, brain ghrelin levels, serum HMGB1 levels, ileal mucosal permeability to fluorescein isothiocyanate dextran, bacterial counts in the mesenteric lymph nodes complex, and gut water content were determined. In additional groups of animals, bilateral trunk vagotomy was performed at 5 hrs after CLP before ghrelin injection. Furthermore, to confirm the role of central ghrelin receptors in ghrelin's effect, ghrelin (1 nmol) was administered through intracerebroventricular injection at 5 hrs after CLP. Our results showed that brain levels of ghrelin decreased by 34% at 20 hrs after CLP. Intravenous administration of ghrelin completely restored brain levels of ghrelin, significantly reduced the elevated HMGB1 levels, and attenuated gut barrier dysfunction. Vagotomy eliminated ghrelin's inhibition of HMGB1 and attenuation of gut barrier dysfunction. Intracerebroventricular injection of ghrelin decreased serum HMGB1 levels and ameliorated gut barrier dysfunction. CONCLUSIONS:Ghrelin reduces serum HMGB1 levels and ameliorates gut barrier dysfunction in sepsis by vagus nerve activation via central ghrelin receptors. Ghrelin can be further developed as a novel agent to protect gut barrier function in sepsis.
Authors: H Wang; O Bloom; M Zhang; J M Vishnubhakat; M Ombrellino; J Che; A Frazier; H Yang; S Ivanova; L Borovikova; K R Manogue; E Faist; E Abraham; J Andersson; U Andersson; P E Molina; N N Abumrad; A Sama; K J Tracey Journal: Science Date: 1999-07-09 Impact factor: 47.728
Authors: Shiguang Liu; Donna B Stolz; Penny L Sappington; Carlos A Macias; Meaghan E Killeen; Jyrki J Tenhunen; Russell L Delude; Mitchell P Fink Journal: Am J Physiol Cell Physiol Date: 2005-11-09 Impact factor: 4.249
Authors: Jonas Sundén-Cullberg; Anna Norrby-Teglund; Ari Rouhiainen; Heikki Rauvala; Gunilla Herman; Kevin J Tracey; Martin L Lee; Jan Andersson; Leif Tokics; Carl Johan Treutiger Journal: Crit Care Med Date: 2005-03 Impact factor: 7.598
Authors: Sabrina Diano; Susan A Farr; Stephen C Benoit; Ewan C McNay; Ivaldo da Silva; Balazs Horvath; F Spencer Gaskin; Naoko Nonaka; Laura B Jaeger; William A Banks; John E Morley; Shirly Pinto; Robert S Sherwin; Lin Xu; Kelvin A Yamada; Mark W Sleeman; Matthias H Tschöp; Tamas L Horvath Journal: Nat Neurosci Date: 2006-02-19 Impact factor: 24.884
Authors: Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon Journal: Best Pract Res Clin Endocrinol Metab Date: 2011-10 Impact factor: 4.690
Authors: Sjoerd H W van Bree; Andrea Nemethova; Cathy Cailotto; Pedro J Gomez-Pinilla; Gianluca Matteoli; Guy E Boeckxstaens Journal: Nat Rev Gastroenterol Hepatol Date: 2012-07-17 Impact factor: 46.802
Authors: Gerald S Supinski; Lin Wang; Elizabeth A Schroder; Leigh Ann P Callahan Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-05-27 Impact factor: 5.464